Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best biotech stocks with high potential. H.C. Wainwright analyst Joseph Pantginis reiterated a bullish stance on Viking Therapeutics, Inc. (NASDAQ:VKTX) on September 22, giving the stock a Buy rating with a $102 price target.
The analyst supported the rating with Viking Therapeutics, Inc.’s promising market position, stating that the company’s competitive efficacy and safety data from its oral and subcutaneous GLP-1 programs take the lead as its notable strengths.
The same day, BTIG analyst Justin Zelin also reiterated a Buy rating on Viking Therapeutics, Inc. and set a $125.00 price target, supporting the rating with the company’s solid position in the metabolic disease and obesity market.
Viking Therapeutics, Inc. is a clinical-stage company that develops therapies for metabolic and endocrine disorders.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
